How effective is Methotrexate for Psoriasis? (a real world drug study)
Summary:
Overall ratings: 3.1/5 Long term ratings: 3.3/5
This is a phase IV clinical study of how effective Methotrexate (methotrexate sodium) is for Psoriasis and for what kind of people. The study is created by eHealthMe from 167 Methotrexate users and is updated continuously.
What is Methotrexate?
Methotrexate has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 604,312 Methotrexate users. Check the latest studies of Methotrexate.
What is Psoriasis?
Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,476 drugs and 1,694 conditions by eHealthMe. Check the latest studies of Psoriasis.
167 people are studied for taking Methotrexate in Psoriasis
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Methotrexate effectiveness for Psoriasis (number of people):
Overall:
- not at all: 8
- somewhat: 47
- moderate: 48
- high: 48
- very high: 16
Long Term:
- not at all: 1
- somewhat: 16
- moderate: 27
- high: 23
- very high: 7
Gender of people who take Methotrexate for Psoriasis *:
- female: 67.07 %
- male: 32.93 %
Age of people who take Methotrexate for Psoriasis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 2.4 %
- 20-29: 11.38 %
- 30-39: 12.57 %
- 40-49: 24.55 %
- 50-59: 30.54 %
- 60+: 18.56 %
Who find Methotrexate more effective for Psoriasis?
Gender of people who take Methotrexate for Psoriasis *:
- female: 70.31 %
- male: 29.69 %
Age of people who take Methotrexate for Psoriasis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 4.69 %
- 20-29: 7.8100000000000005 %
- 30-39: 10.94 %
- 40-49: 21.88 %
- 50-59: 31.25 %
- 60+: 23.44 %
* Approximation only. Some reports may have incomplete information.
Do you take Methotrexate?
- You can start a phase IV clinical trial to monitor Methotrexate safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
- Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Methotrexate (604,312 reports)
Treatments, associated drugs and conditions:
- Psoriasis (508,163 reports)
How the study uses the data?
The study is based on methotrexate sodium (the active ingredients of Methotrexate) and Methotrexate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Tudorza Pressair and Heparin - a second ago
- Could Calcium cause Visual Impairment? - 10 seconds ago
- Drug interactions of Thiamine Hydrochloride and Thiamine - 14 seconds ago
- Could Copegus cause Hepatic Steatosis? - 33 seconds ago
- Drug interactions of Januvia and Tudorza Pressair - 33 seconds ago
- Drug interactions of Lyrica and Allopurinol Sodium - 41 seconds ago
- Could Benadryl cause Urination - Excessive At Night? - 42 seconds ago
- Drug interactions of Tenormin and Lactobacillus - 45 seconds ago
- How effective is Cephalexin for Strep Throat? - 55 seconds ago
- Could Symbicort cause Depression? - a minute ago